May 17, 2020 — Cindy Grines, M.D., MSCAI, a world-renowned physician credited for pioneering percutaneous coronary intervention (PCI) for heart attacks, has assumed the office of president of the Society for Cardiovascular Angiography and Interventions (SCAI). Grines’ tenure as president officially begans Saturday, May 16, during the SCAI 2020 Scientific Sessions Virtual Conference. Grines is the third female interventionalist to lead the society.

May 15, 2020 – A groundbreaking trial recently examined the viability of telemedicine for remote guidance of a population-based ST-segment elevation myocardial infarction (STEMI) program reaching more than 100 million patients. The study, presented as late-breaking science during the Society for Cardiovascular Angiography and Interventions (SCAI) 2020 Virtual Conference. 

May 15, 2020 – A late-breaking study aimed to evaluate whether optical coherence tomography (OCT) can predict fractional flow reserve (FFR) values and assess if OCT parameters may predict clinical outcome in patients with negative FFR.

CMS now reimburses for outpatient center same-day percutenous coronary intervention but SCAI says quality guidelines need to be met. SCAI Expert Consensus Statement on Out of Hospital Cardiac Arrest. Catheterization and Cardiovascular Interventions

May 15, 2020 – The Society for Cardiovascular Angiography and Interventions (SCAI) issued a position statement on the performance of percutaneous coronary intervention (PCI) in ambulatory surgical centers (ASCs) during its 2020 virtual meeting.[1] The document was also published in SCAI’s official journal, Catheterization and Cardiovascular Interventions.
New York City newspaper headlines from April 1, 2020, and masked police officers at a subway station in Manhattan clearly outline the issues facing the city's hospitals during the height of COVID-19 pandemic in New York. Photo by Mike Borchardt. How Cardiology Dealt With the COVID-19 Surge in New York City

Over the past three months COVID-19 has dominated nearly all healthcare news, so it is not surprising that the virus highlighted the opening sessions of the Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions 2020 Virtual Conference, May 14-16, 2020.

May 14, 2020 – Medtronic announced results from late-breaking clinical trials evaluating the MyCareLink Heart mobile app and the Micra Transcatheter Pacing System (TPS), products that provide needed care for patients and optimal management of their symptoms – while reducing potential exposure between patients and their clinicians. During the current COVID-19 pandemic, procedures and therapies that reduce exposure to other people are important because that also reduces the potential for spreading the virus.

This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center, explains the SCAI precaution guidelines for treating patients in the cath lab under the COVID-19 pandemic. He explains the how cardiology departments in the U.S. are operating to treat acute patients during novel coronavirus (COVID-19, SARS-CoV-2) containment efforts.

May 13, 2020 — Cardiac resynchronization therapy (CRT) using biventricular pacing (BVP) or His bundle pacing (HBP) is effective in patients with heart failure (HF), bundle branch block or RV pacing.

May 13, 2020 — The PRECEPT study testing the use of the Biosense Webster Thermocool Smarttouch SF Catheter for the treatment of persistent atrial fibrillation (AF), resulted in freedom from any documented, symptomatic atrial arrhythmias at 15 months post-procedure for eight out of ten study participants (80.4 percent).[1] The trial was presented as a late-breaking study at the Heart Rhythm Society (HRS) 2020 Science virtual meeting.

May 13, 2020 — The patient-administered nasal spray drug etripamil did not meet its primary endpoint in treating patients with paroxysmal supraventricular tachycardia (PSVT), according to th results of the NODE-301 Trial presented as a late-breaking study at the Heart Rhythm Society (HRS) 2020 virtual meeting.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now